Search research articles
Contact Us
Filters
Showing results (101-110 of 111) with videos related to
Page
of 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 10, 2012
Acute lymphoblastic leukemia
Joseph C Alvarnas, Patrick A Brown, Patricia Aoun, et al.
The Journal of Clinical Investigation
|
March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome
Houda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Blood Advances
|
July 5, 2022
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML
Karilyn T Larkin, Deedra Nicolet, Benjamin J Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Nature Medicine
|
October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd, Ross L Levine, Amy S Ruppert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
The Journal of Clinical Investigation
|
September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 111) with videos related to
Sort By:
Page
of 12
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 10, 2012
Acute lymphoblastic leukemia
Joseph C Alvarnas, Patrick A Brown, Patricia Aoun, et al.
The Journal of Clinical Investigation
|
March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome
Houda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Blood Advances
|
July 5, 2022
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML
Karilyn T Larkin, Deedra Nicolet, Benjamin J Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Nature Medicine
|
October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd, Ross L Levine, Amy S Ruppert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
The Journal of Clinical Investigation
|
September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Page
of 12